Genetic variation within adrenergic pathways determines in vivo effects of presynaptic stimulation in humans

Circulation

Volumn 117, Issue 4, 2008, Pages 517-525

  Fung, Maple M ^a   Nguyen, Carie ^a   Mehtani, Parag ^a   Sale, Rany M ^a   Perez, Brandon ^a   Thomas, Brenda ^a   Das, Madhusudan ^a   Schork, Nicholas J ^a   Mahata, Sushil K ^a   Ziegler, Michael G ^a   O'Connor, Daniel T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Catecholamines; Genes; Genetics; Hypertension; Veins

Indexed keywords

CATECHOLAMINE; CHROMOGRANIN B; CYTOCHROME B; CYTOCHROME B561; DIMETHYLANILINE MONOOXYGENASE; DIMETHYLANILINE MONOOXYGENASE 3; NORADRENALIN; PROTEIN; TYRAMINE; UNCLASSIFIED DRUG; CHGB PROTEIN, HUMAN;

ADRENERGIC SYSTEM; ADULT; ARTICLE; BLOOD VESSEL REACTIVITY; CATALYSIS; CATECHOLAMINERGIC SYSTEM; CONCENTRATION (PARAMETERS); EXON; FAMILY HISTORY; FEMALE; GENE FREQUENCY; GENE LOCUS; GENE TARGETING; GENETIC VARIABILITY; HUMAN; HYPERTENSION; IN VIVO STUDY; MALE; NERVE STIMULATION; NORMAL HUMAN; PHENOTYPE; PRESYNAPTIC NERVE; PRIORITY JOURNAL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; VENOCONSTRICTION; BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFECT; ETHNIC GROUP; FAMILY HEALTH; GENETICS; INHERITANCE; MIDDLE AGED; PHYSIOLOGY; SYNAPTOSOME; VASOCONSTRICTION;

ADULT; BLOOD PRESSURE; CATECHOLAMINES; CHROMOGRANIN B; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHNIC GROUPS; FAMILY HEALTH; FEMALE; HUMANS; HYPERTENSION; INHERITANCE PATTERNS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PRESYNAPTIC TERMINALS; SEX FACTORS; TYRAMINE; VARIATION (GENETICS); VASOCONSTRICTION;

EID: 41049113284     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.706317     Document Type: Article

References (50)

1. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290:199-206.
2. Ward R. Familial aggregation and genetic epidemiology of blood pressure. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis and Management. New York, NY: Raven Press; 1990:81-100.
3. Grassi G. Role of the sympathetic nervous system in human hypertension. J Hypertens. 1998;16:1979-1987.
4. Goldstein DS. Plasma catecholamines and essential hypertension: an analytical review. Hypertension. 1983;5:86-99.
5. Chitbangonsyn SW, Mahboubi P, Walker D, Rana BK, Diggle KL, Timberlake DS, Parmer RJ, O'Connor DT. Physical mapping of autonomic/sympathetic candidate genetic loci for hypertension in the human genome: a somatic radiation hybrid library approach. J Hum Hypertens. 2003;17:319-324.
6. 3 subunit genes in the Japanese population: the Suita study. Hypertens Res. 2004;27:31-37.
7. 2-adrenergic receptor gene, hypertension, and obesity in the Olivetti heart study. Am J Hypertens. 2004;17:718-720.
8. 2 adrenergic receptor on the agonist mediated vascular desensitization. N Engl J Med. 2001;345:1030-1035.
9. King D, Etzel JP, Chopra S, Smith J, Cadman PE, Rao F, Funk SD, Rana BK, Schork NJ, Insel PA, O'Connor DT. Human response to alpha2-adrenergic agonist stimulation studied in an isolated vascular bed in vivo: biphasic influence of dose, age, gender, and receptor genotype. Clin Pharm Ther. 2005;77:388-403.
10. Aellig WH. Clinical pharmacology, physiology, and pathophysiology of superficial veins, 1. Br J Clin Pharmacol. 1994;38:181-196.
11. Aellig WH. Clinical pharmacology, physiology, and pathophysiology of superficial veins, 2. Br J Clin Pharmacol. 1994;38:289-305.
12. Buetow KH, Edmondson M, MacDonald R, Clifford R, Yip P, Kelley J, Little DP, Strausberg R, Koester H, Cantor CR, Braun A. Highthroughput development and characterization of a genome-wide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proc Natl Acad Sci U S A. 2001;98:581-584.
13. Ferraris A, Rappaport E, Santacroce R, Pollak E, Krantz I, Toth S, Lysholm F, Margaglione M, Restagno G, Dallapiccola B, Surrey S, Fortina P. Pyrosequencing for detection of mutations in the connexin 26 (GJB2) and mitochondrial 12S RNA (MTRNR1) genes associated with hereditary hearing loss. Hum Mutat. 2002;20:312-320.
14. Ronaghi M. Pyrosequencing sheds light on DNA sequencing. Genome Res. 2001;11:3-11.
15. Simes RJ. An improved Bonferroni procedure for multiple tests of significance. Biometrika. 1986;73:751-754.
16. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B. 1995;57:289-300.
17. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2003;39:175-191.
18. Nievergelt CM, Libiger O, Schork NJ. Generalized analysis of molecular variance. PLoS Genet. 2007;3:e51.
19. Kennedy B, Ziegler MG. A more sensitive and specific radioenzymaticassay for catecholamines. Life Sci. 1990;47:2143-2153.
20. Chalon S, Moreno H Jr, Benowitz NL, Hoffman BB, Blaschke TF. Nicotine impairs endothelium-dependent dilatation in human vein in vivo. Clin Pharmacol Ther. 2000;67:391-397.
21. Holmes C, Moak J, Eldadah B, Zimmerly E, Sharabi Y, Goldstein DS. Dopamine contamination of infused tyramine. Clin Chem. 2005;51:1733-1735.
22. Rana BK, Insel PA, Payne SH, Abel K, Beutler E, Ziegler MG, Schork NJ, O'Connor DT. Population-based sample reveals gene-gender interactions in blood pressure in white Americans. Hypertension. 2007;49:96-106.
23. Goldstein DS, Nurnberger J, Simmons S, Gershon ES, Polinsky R, Keiser HK. Effects of injected sympathomimetic amines on plasma catecholamine and circulatory variables. Life Sci. 1982;32:1057-1063.
24. Frewin DB, Whelan RF. The mechanism of action of tyramine on the blood vessels of the forearm in man. Br J Pharmacol Chemo Ther. 1968;33:105-116.
25. Taupenot L, Harper KL, O'Connor DT. Mechanism of disease: the chromogranin-secretogranin family. N Engl J Med. 2003;348:1134-1149.
26. Aellig WH. A new technique for recording compliance of human hand veins. Br J Clin Pharmacol. 1981;11:237-243.
27. Sicuteri F, Del Bianco PL, Anselmi B. Morphine abstinence and serotonin supersensitivity in man: analogies with the mechanism of migraine? Psychopharmacology (Berl). 1979;65:205-209.
28. Faraj BA, Bowen PA, Isaacs JW, Rudman D. Hypertyraminemia in cirrhotic patients. N Engl J Med. 1976;294:1360-1364.
29. Berry MD. Mammalian central nervous system trace amines: pharmacologic amphetamines, physiologic neuromodulators. J Neuro Chem. 2004;90:257-271.
30. Brandao F, Rodrigues-Pereira E, Monteiro JG, Davidson R. A kinetic study of the release of noradrenaline by tyramine. Arch Pharmacol. 1981;318:83-87.
31. Borowsky B, Adham N, Jones KA, Raddatz R, Artymyshyn R, Ogozalek KL, Durkin MM, Laklani PP, Bonini JA, Pathirana S, Boyle N, Pu X, Kouranova E, Lichtblau H, Ochoa FY, Branchek TA, Gerald C. Trace amines: identification of a family of mammalian G protein coupled receptors. Proc Natl Acad Sci U S A. 2001;98:8966-8971.
32. Martin SA, Alexieva S, Carruthers SG. The influence of age on dorsal hand vein responsiveness to norepinephrine. Clin Pharmacol Ther. 1986;40:257-260.
33. Sundlof G, Wallin BG. The variability of muscle nerve sympathetic activity in resting recumbent man. J Physiol (London). 1977;272:383-397.
34. Fagius J, Wallin BG. Long term variability and reproducibility of resting human muscle nerve sympathetic nerve activity at rest, as reassessed after a decade. Clin Auton Res. 1993;3:201-205.
35. Okuyama E, Yamamoto R, Ichikawa Y, Tsubaki M. Structural basis for the electron transfer across the chromaffin vesicle membranes catalyzed by cytochrome b561: analyses of cDNA nucleotide sequences and visible absorption spectra. Biochim Biophys Acta. 1998;1383:269-278.
36. Huh YH, Jeon SH, Yoo SH. Chromogranin B-induced secretory granule biogenesis: comparison with the similar role of chromogranin A. J Biol Chem. 2003;278:40581-40589.
37. Cashman JR, Zhang J. Human flavin-containing monooxygenases. Annu Rev Pharmacol Toxicol. 2006;46:65-100.
38. Camac ho M, Machado JD, Montesinos MS, Criado M, Borges R. Intragranular pH rapidly modulates exocytosis in adrenal chromaffin cells. J Neuro Chem. 2006;96:324-334.
39. Jacob G, Gamboa A, Diedrich A, Shibao C, Robertson D, Biaggioni I. Tyramine induced vasodilation mediated by dopamine contamination. Hypertension. 2005;46:355-359.
40. Poch GR, Kopin IJ. The role of octopamine in tachyphylaxis to tyramine. Biochem Pharmacol. 1966;15:210-212.
41. Harada K, Ohmori M, Kito Y, Fujimura A. Effects of dopamine on veins in humans: comparison with noradrenaline and influence of age. Eur J Clin Pharmacol. 1998;54:227-230.
42. Charkoudian N, Joyner MJ, Johnson CP, Eisenach JH, Dietz NM, Curry TB, Wallin BG. Vascular adrenergic responsiveness is inversely related to tonic activity of sympathetic vasoconstrictor nerves in humans. J Physiol. 2006;572(pt 3):821-827.
43. Ferrier C, Cox H, Esler M. Elevated total body noradrenaline spillover in normotensive members of hypertensive families. Clin Sci. 1993;84:225-230.
44. Bachmann AW, Ballantine DM, Gordon RD. Effect of positive family history of hypertension on the blood pressure and catecholamine responses to a 6 hour adrenaline infusion. Clin Exp Pharmacol Physiol. 1993;20:395-398.
45. Rumantir MS, Kaye DM, Jennings GL, Vaz M, Hastings JA, Esler MD. Phenotypic evidence of faulty neuronal norepinephrine reuptake in essential hypertension. Hypertension. 2000;36:824-829.
46. Jie K, Van Brummelen P, Vermey P, Timmermans PBMWM, Van Zwieten PA. Post-synaptic α1 and α2 adrenoreceptors in human blood vessels: interactions with exogenous and endogenous catecholamines. Eur J Clin Invest. 1987;17:174-181.
47. Schafers RF, Poller U, Ponicke K, Geissler M, Daul AE, Michel MC, Brode O-E. Influence of adrenoreceptor and muscarinic receptor blockade on the cardiovascular effects of exogenous noradrenaline and of endogenous noradrenaline released by infused tyramine. Naunyn Schmiedebergs Arch Pharmacol. 1997;355:239-249.
48. Scriven AJ, Dollery CT, Murphy MB, Macquin I, Brown MJ. Blood pressure and plasma norepinephrine concentrations after endogenous norepinephrine release by tyramine. Clin Pharmacol Ther. 1983;33:710-716.
49. Stein CM, Deegan R, Wood AJJ. Lack of correlation between arterial and venous β-adrenergic receptor sensitivity. Hypertension. 1997;29:1273-1277.
50. Stein CM, Nelson R, Brown M, He H, Deegan R, Wood M, Wood AJJ. Forearm beta-adrenergic receptor-mediated vasodilation is impaired without alteration of norepinephrine spillover in borderline hypertension. J Clin Invest. 1995;96:579-585.